DRW Securities’s Pacira BioSciences PCRX Stock Holding History

DRW Securities’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-10,100	Closed	-$341K	–	95
2016 Q2	$341K	Buy	+10,100	New	+$496K	0.02%	53

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DRW Securities's PCRX Position: Q3 2016 in Review

DRW Securities sold out of Pacira BioSciences (PCRX) in Q3 2016, closing a stake of 10,100 shares — an estimated $341K sold.

DRW Securities first reported a position in PCRX in Q2 2016 and held it in 1 quarter. The position peaked at $341K in Q2 2016. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

DRW Securities reported no remaining Pacira BioSciences position as of Q3 2016 after selling out during the quarter.
DRW Securities sold 10,100 Pacira BioSciences shares in Q3 2016, an estimated $341K.
DRW Securities first reported a position in Pacira BioSciences in Q2 2016 and held it in 1 quarter.
DRW Securities's Pacira BioSciences position peaked at $341K in Q2 2016.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on DRW Securities's 13F filing for Q3 2016, filed 14 Nov 2016.